Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Calcium signaling pathway | R-HSA-381753 | map04020 | thapsigargin | 2724387 | drug-path |
| Basal cell carcinoma | R-HSA-5626181 | map05217 | thapsigargin | 2724387 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | thapsigargin | 2724387 | drug-path |
| Prostate cancer | R-HSA-2990872 | map05215 | thapsigargin | 2724387 | drug-path |
| DNA replication | R-HSA-69306 | map03030 | thapsigargin | 2724387 | drug-path |
| Basal transcription factors | R-HSA-3232118 | map03022 | thapsigargin | 2724387 | drug-path |
| Small cell lung cancer | R-HSA-5619066 | map05222 | thapsigargin | 2724387 | drug-path |
| Huntington's disease | R-HSA-1643685 | 0 | ascorbic acid | 2761171 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | ascorbic acid | 2761171 | drug-path |
| Parkinson's disease | R-HSA-1643685 | 0 | ascorbic acid | 2761171 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | ascorbic acid | 2761171 | drug-path |
| Graft-versus-host disease | R-HSA-1643685 | map05332 | hydroflumethiazide | 8982 | drug-path |
| Autoimmune thyroid disease | R-HSA-1643685 | map05320 | hydroflumethiazide | 8982 | drug-path |
| Antigen processing and presentation | R-HSA-1236975 | map04612 | hydroflumethiazide | 8982 | drug-path |
| Cell adhesion molecules (CAMs) | R-HSA-1031690 | 0 | hydroflumethiazide | 8982 | drug-path |
| Allograft rejection | R-HSA-9679028 | map05330 | hydroflumethiazide | 8982 | drug-path |
| Type I diabetes mellitus | R-HSA-5683209 | map04940 | hydroflumethiazide | 8982 | drug-path |
| Apoptosis | R-HSA-109581 | map04210 | hydroflumethiazide | 8982 | drug-path |
| Hematopoietic cell lineage | R-HSA-173752 | map04640 | acetazolamide | 1986 | drug-path |
| Amyotrophic lateral sclerosis (ALS) | Q8NDH6-2 | 0 | acetazolamide | 1986 | drug-path |